2023–2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states
During the 2023-2024 respiratory virus season, COVID-19 vaccine uptake among the immunocompromised in these 2 states was low, with fewer than 21 % receiving a 2023-2024 dose. Enhanced efforts to increase COVID-19 vaccine uptake in this vulnerable population are needed.
Authors
- Benjamin T. Carter (ORCID: https://orcid.org/0000-0001-6598-2744)
- Laura Puzniak (ORCID: https://orcid.org/0000-0001-8697-9683)
- Santiago M. C. Lopez (ORCID: https://orcid.org/0000-0001-7714-1707)
- Leah J. McGrath (ORCID: https://orcid.org/0000-0002-0312-635X)
- Kathleen M. Andersen (ORCID: https://orcid.org/0000-0003-2670-800X)
- Tiange Yu (ORCID: https://orcid.org/0009-0009-8854-7142)
- Farid Khan (ORCID: https://orcid.org/0000-0003-3754-555X)
- John M. McLaughlin
- Matthew Brouillette
Institutions
- Pfizer (United States) (US)
Publication Details
- Journal
- Vaccine
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127120
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- Pfizer